Lv1
38 积分 2025-07-11 加入
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
24天前
已完结
PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
24天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
24天前
已完结
Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer
1个月前
已完结
Immune-related adverse events of checkpoint inhibitors
1个月前
已完结
A Novel Attenuated CD122-Biased IL15 Mutein Promotes Strong NK and T Cell–Dependent Antitumor Immunity
2个月前
已完结
Cloning and sequencing of the cynomolgus monkey prostate specific antigen cDNA
2个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2个月前
已完结
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
皖公网安备34019202002308
